【摘要】 目的:探讨人尿激肽原酶治疗急性脑梗死的效果及对血管内皮生长因子和神经生长因子的影响。方法:选取2017年10月-2018年8月本院收治的急性脑梗死患者60例,按照随机数字表法分为对照组和观察组,每组30例,其中对照组采用常规治疗,观察组在对照组基础上加用人尿激肽原酶。检测治疗前后两组患者血管内皮生长因子和神经生长因子水平、NIHSS和ADL评分,并评估治疗效果。结果:与治疗前比较,治疗第7天两组血清血管内皮生长因子和神经生长因子水平显著升高、NIHSS评分显著降低、ADL评分显著提高,而观察组变化幅度均明显大于对照组,差异均有统计学意义(P<0.05);根据NIHSS评分及ADL评分,观察组总有效率为90.00%、80.00%,显著高于对照组的76.67%、63.33%,差异均有统计学意义(P<0.05)。结论:人尿激肽原酶可明显改善急脑梗死患者的神经功能及日常生活能力,提高血清血管内皮生长因子和神经生长因子水平,保护神经细胞,改善侧支循环,提高急性脑梗死的疗效。更多还原

【Abstract】 Objective:To probe into the efficacy of Human Urinary Kallikrein in treatment of acute cerebral infarction and its effect on VEGF and NGF levels.Method:A total of 60 patients with acute cerebral infarction from Oct 2017 to Aug 2018 were selected and divided into the control group and the observation group,30 cases in each group.The control group was given routine treatment,and the observation group was given Human Urinary Kallikrein based on routine treatment.The levels of VEGF,NGF and the NIHSS,ADL scores of two groups were detected before and after treatment,and the therapeutic effect was evaluated.Result:Compared with those of before treatment,the serum VEGF and NGF levels of two groups were significantly increased,the NIHSS scores were significantly decreased,and the ADL scores were increasing trend on the 7 th day of treatment,and the rangeability of the observation group was more significant than that of control group,there were statistical significance(P<0.05).According to NIHSS score and ADL score,the total effective rate of the observation group were 90.00% and 80.00%,they were significantly higher than 76.67% and 63.33% of the control group,there were statistical significance(P<0.05).Conclusion:Human Urinary Kallikrein can significantly improve the neurological function,activities of daily living,the serum VEGF and NGF levels of ACI patients,with protect nerve cells,increase collateral circulation,improve clinical symptoms.更多还原